| Autor: |
Wyant T; Millennium Pharmaceuticals, Cambridge, MA, USA. wyant@mpi.com, Lackey A, Green M |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of translational medicine [J Transl Med] 2008 Dec 01; Vol. 6, pp. 76. Date of Electronic Publication: 2008 Dec 01. |
| DOI: |
10.1186/1479-5876-6-76 |
| Abstrakt: |
Pharmacodynamic assays are important in clinical trial design to investigate the relationship between drug concentration (pharmacokinetics) and drug "effect' or biological activity. Increasingly flow cytometry is being used to examine the pharmacodynamic effect of new drug entities. However, to date, the analytical validation of cytometry based assays is limited and there is no suitable guidance for method validation of flow cytometry-based pharmacodynamic assays. Here we report the validation of a flow cytometry-based chemokine internalization assay for use in evaluating the effect of a receptor antagonist in clinical trials. The assay method was validated by examining the stability of the reagent, assay robustness, sensitivity, repeatability and reproducibility precision. Experimental results show the assay reagent was stable over 26 weeks. The assay demonstrated a sensitivity to distinguish 0.005 microg/ml of a CCR2 antagonist with a %CV of 13.3%. The intra-assay repeatability was less than 15% with an inter-assay repeatability of less than 20%. In vivo study results demonstrated that the assay was consistent and a reliable measure of antagonist activity. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink